Clinical trial
A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With…
NCT00381810 · Genentech, Inc., Industry · Terminated
Key facts
| NCT number | NCT00381810 |
|---|---|
| Title | A Study to Evaluate the Safety of Rituximab Retreatment in Subjects With Systemic Lupus Erythematosus |
| Official title | An Open-label, Single-arm, Multicenter Phase II/III Extension Study to Evaluate the Safety of Rituximab Re-treatment in Subjects With Moderate to Severe Systemic Lupus Erythematosus Previously Enrolled in Protocol U2971g |
| Acronym | VOYAGER |
| Lead sponsor | Genentech, Inc., Industry |
| Status | Terminated |
| Phase | Phase 3 |
| Study type | Interventional |
| Conditions | Lupus Erythematosus, Systemic |
| Intervention type | Drug |
| Interventions | Rituximab, Methylprednisolone, Acetaminophen, Diphenhydramine |
| Enrollment | 31 |
| Start date | Jun 22, 2006 |
| Primary completion | Jul 31, 2008 |
| Completion | Feb 29, 2012 |
| First posted | Sep 28, 2006 |
| Last update posted | Aug 1, 2017 |
| Countries | United States |
At a glance
- 10–99 Study sites
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: